Exosome Therapy: What It Is, How It Works, and What the Evidence Actually Shows
Explore the clinic directoryIn this article
Exosome activation is the step where exosomes, the 30 to 150 nanometer vesicles released by mesenchymal stem cells (MSCs), bind to a target cell and switch on its repair signaling: in a 2018 Biomaterials study by Zhang and colleagues, MSC exosomes activated AKT and ERK signaling in cartilage cells through the enzyme CD73. Exosome therapy uses these cell-free vesicles instead of live stem cells, and as of 2026 the FDA has approved no exosome product for any clinical use, so every treatment offered in US clinics remains investigational.
At a Glance
Next step: Read the exosome therapy guide, then browse vetted clinics that list exosome modalities.
- What it is: A cell-free regenerative therapy using exosomes, tiny signaling vesicles released by mesenchymal stem cells, instead of live cells.
- How it works: Exosomes deliver growth factors, microRNA, and anti-inflammatory signals to target tissues via paracrine signaling. Once taken up, that cargo activates repair pathways such as AKT and ERK inside the recipient cell.
- FDA status: No exosome products are FDA-approved for any clinical use. All treatments are investigational.
- Evidence level: Promising preclinical data; limited and early human evidence for most applications.
- Cost: $3,000-$10,000+ per treatment session, not covered by insurance.
- Safety: The FDA has issued multiple warnings about unregulated exosome products. Quality control varies dramatically between clinics.
Next step: Read the regenerative therapy guide, then find vetted clinics.
If you’ve been researching regenerative medicine, you’ve probably come across exosome therapy, and probably some wildly inflated claims about it. Here is the honest picture: exosome science is genuinely fascinating, the preclinical data is compelling, and the theoretical advantages over traditional stem cell therapy are real. But marketing has outpaced evidence, and the regulatory field is something you need to understand before spending thousands of dollars.
The sections below cover what exosomes are, how exosome activation works inside a target cell, how the therapy is delivered, what the research does and doesn’t support, what it costs, and how to protect yourself from low-quality products. For a shorter reference on product sources and regulation, the exosome therapy treatment guide covers terms and FDA status in one page.
Key Takeaways
- Exosomes are extracellular vesicles 30 to 150 nanometers across that carry proteins, lipids, mRNA and microRNA between cells, as described in a 2020 review in Science by Raghu Kalluri and Valerie LeBleu.
- Exosome activation of a target cell has been mapped in the lab: Zhang and colleagues (Biomaterials, 2018) showed MSC exosomes activate AKT and ERK signaling in cartilage cells through CD73 and adenosine.
- The FDA stated in its December 2019 Public Safety Notification that there are no FDA-approved exosome products, after serious adverse events in patients in Nebraska treated with unapproved products.
- Orthopedic use for knee osteoarthritis has the most human data, but published studies are small, typically under 50 patients, with no large randomized controlled trial.
- PRP has a larger evidence base than exosomes for knee osteoarthritis and androgenetic alopecia, at a lower cost per session.
- A legitimate product comes with a Certificate of Analysis showing particle count, size range, the surface markers CD63, CD81 and CD9, and sterility and endotoxin testing.
What Are Exosomes and Why Do They Matter?
Exosomes are nanoscale extracellular vesicles, tiny membrane-bound packages between 30 and 150 nanometers in diameter, secreted by virtually every cell in your body. Think of them as biological text messages: they carry cargo (proteins, lipids, mRNA, and microRNA) from a parent cell to a recipient cell, delivering instructions that change how the recipient cell behaves.
Researchers increasingly use the broader term extracellular vesicles (EVs), or small EVs, because standard lab methods cannot always separate true exosomes from other vesicles of similar size. The International Society for Extracellular Vesicles sets reporting standards for this field in its MISEV2018 position statement by Théry and colleagues. In clinics, the same products are sold as exosome injections, exosome IV, MSC-derived exosomes or secretome products.
When mesenchymal stem cells (MSCs) release exosomes, that cargo is loaded with regenerative signaling molecules: growth factors like VEGF and TGF-β, anti-inflammatory cytokines like IL-10, and regulatory microRNAs that can switch genes on or off in target cells. This is called paracrine signaling, and researchers now believe it’s actually the primary way stem cells exert their therapeutic effects. In other words, the healing power of stem cells may not come from the cells themselves; it comes from the messages they send.
That insight is what makes exosome therapy so interesting: if the signals are what matter, maybe you don’t need to transplant living cells at all.
Key Concept: Paracrine Signaling: For years, scientists assumed stem cells worked by engrafting into damaged tissue and replacing injured cells. We now understand that most of their benefit comes from the signaling molecules they release, especially through exosomes. This “paracrine hypothesis” has reshaped regenerative medicine and is the scientific foundation for exosome therapy.
How Exosome Therapy Differs from Stem Cell Therapy
This is the question asked most often: “If exosomes come from stem cells, why not just use stem cells?” Fair question. Here’s how they compare.
Stem cell therapy transplants living cells that can engraft, differentiate, and continue producing signals over time. Exosome therapy delivers a concentrated dose of those signals without any living cells. Each approach has trade-offs.
Exosomes are smaller, easier to store (they can be freeze-dried), carry lower immune rejection risk since they contain no cellular machinery, and may be safer for certain patients. But they also lack the sustained signaling that a living cell population provides, and their effects may be more temporary.
Both approaches sit in the same regulatory position for most uses: they are cash pay and largely investigational. The stem cell therapy treatment guide explains which cell products have narrow FDA approvals, and the comparison of PRP and stem cell therapy shows where each has stronger human data.
Three Core Mechanisms
Cell Signaling
Exosomes deliver microRNA and growth factors that reprogram target cell behavior, stimulating proliferation, reducing apoptosis (cell death), and activating tissue-specific repair pathways. This intercellular communication network is what coordinates the body’s regenerative response after injury.
Tissue Repair
MSC-derived exosomes promote angiogenesis (new blood vessel formation), stimulate collagen production, enhance fibroblast migration, and support chondrocyte proliferation in cartilage. These mechanisms collectively accelerate wound healing and tissue regeneration at the cellular level.
Immune Modulation
Exosomes carry anti-inflammatory cytokines (IL-10, TGF-β) and regulatory microRNAs that shift the immune system from a pro-inflammatory state toward resolution and repair. They can suppress overactive immune responses while supporting appropriate immune surveillance.
What Does Exosome Activation Mean?
Exosome activation most often refers to what happens when an exosome reaches a target cell: surface proteins on the vesicle bind to the cell, the cell takes the vesicle in, and the delivered cargo switches on signaling pathways that drive proliferation, migration and repair. The term is also used for priming stem cells so they release more potent exosomes, and, in clinic marketing, for preparing a freeze-dried product before injection. These three meanings carry very different levels of evidence.
How do exosomes activate target cells?
Exosomes dock onto recipient cells through surface proteins such as the tetraspanins CD9, CD63 and CD81 and adhesion molecules called integrins. The cell then absorbs the vesicle by endocytosis or membrane fusion, which releases its microRNA, proteins and lipids inside. That cargo activates intracellular pathways, most often described as PI3K/AKT and ERK, which tell the cell to divide, move toward an injury and resist programmed cell death.
The clearest example comes from cartilage research. According to Zhang and colleagues at the National University of Singapore (Biomaterials, 2018), MSC exosomes repaired osteochondral defects in rats through exosomal CD73, an enzyme that generates adenosine and activates AKT and ERK signaling in chondrocytes. Blocking AKT or ERK suppressed the exosome effect on cell proliferation and migration. The treated defects also showed more CD163-positive M2 repair macrophages than CD86-positive M1 inflammatory macrophages, along with lower IL-1β and TNF-α.
Platelet-derived exosomes work through similar switches. Tao and colleagues (Theranostics, 2017) reported that exosomes isolated from human platelet-rich plasma activated the Akt/Bad/Bcl-2 pathway and reduced bone cell death in a rat model of glucocorticoid-induced osteonecrosis of the femoral head. Both studies are animal and cell culture work, so they explain mechanism rather than show results in patients.
Can stem cells be activated to make stronger exosomes?
Yes, in the laboratory. Researchers precondition MSCs by growing them in low oxygen (hypoxia) or exposing them to inflammatory signals such as interferon gamma or TNF-α, which changes the microRNA and protein content of the exosomes they release. A 2024 review by Zhuo and colleagues in Frontiers in Cell and Developmental Biology summarizes research, largely in cell culture and animal models, in which hypoxic preconditioning increased the biological activity of exosome cargo such as microRNA. Preconditioned products have not been tested against standard exosomes in controlled human trials.
What do clinics mean by “activated” exosomes?
In aesthetic and wellness clinics, “activating” exosomes usually means reconstituting a freeze-dried (lyophilized) vial with sterile saline or water just before it is applied after microneedling or injected. Reconstitution is a preparation step; it does not add potency, and no published trial shows that one mixing protocol works better than another. With platelet-rich plasma, activation has a different meaning: calcium chloride or thrombin is added to make platelets release their growth factors and vesicles.
| What “exosome activation” refers to | What happens | Evidence stage |
|---|---|---|
| Activation of target cells | Exosome cargo switches on AKT, ERK and related repair pathways in recipient cells | Well described in cell culture and animal studies (Zhang 2018; Tao 2017) |
| Preconditioning of source cells | Hypoxia or inflammatory cytokines change the cargo MSCs load into exosomes | Cell culture and animal studies (Zhuo 2024 review) |
| Reconstitution of a clinic product | Freeze-dried exosomes are mixed with sterile fluid before use | A preparation step, not a tested therapeutic variable |
| Activation of PRP | Calcium chloride or thrombin triggers platelets to release growth factors and vesicles | Routine step in PRP preparation |
Whichever meaning a clinic uses, the practical question is the same: what is in the vial. The Certificate of Analysis described in the provider section below is the only document that shows particle count, size and purity.
Sources and Delivery Methods
Most therapeutic exosomes come from mesenchymal stem cells, but the source tissue matters. Umbilical cord-derived MSCs (from Wharton’s jelly) are the most common in commercial products: they’re young, highly proliferative, and produce exosomes with strong regenerative cargo. Bone marrow and adipose-derived MSC exosomes are also used, and some suppliers process placental or amniotic tissue. Emerging research is exploring platelet-derived exosomes (rich in growth factors, similar to PRP) and even plant-derived exosomes from grape and ginger for oral applications.
Delivery depends on the target condition:
- Intra-articular injection: Directly into joints for osteoarthritis and cartilage damage. Ultrasound-guided for precision.
- Intravenous (IV) infusion: For systemic inflammation, neurological conditions, or widespread tissue repair.
- Topical with microneedling: For skin rejuvenation and facial aesthetics.
- Scalp injection: For hair restoration, delivered directly to the follicular region.
- Intrathecal: Into the spinal fluid for neurological applications (research settings only).
The clinicians who offer these routes vary by use. Orthopedic, sports medicine and physical medicine physicians handle joint and tendon injections, dermatologists and aesthetic physicians offer skin and scalp treatments, and integrative physicians and nurse practitioners often run IV protocols. Ask who performs the procedure, not only who owns the clinic.
What the Evidence Actually Shows: Application by Application
The science behind exosomes as biological messengers is well established: hundreds of studies confirm they play critical roles in cell communication and tissue repair. But the gap between “exosomes do interesting things in a petri dish” and “exosome therapy reliably helps patients” is still large for most conditions. Here’s the honest breakdown.
Orthopedic Applications (Osteoarthritis, Tendon Injuries)
Evidence Grade: Promising
This is the area with the most human data. MSC-derived exosomes have shown cartilage-protective effects in animal models, promoting chondrocyte proliferation and reducing inflammatory cytokines like IL-1β and TNF-α. Several small human studies (typically under 50 patients) report improvements in knee osteoarthritis pain scores and function following intra-articular exosome injections. However, no large randomized controlled trial has been published, and we don’t have long-term durability data. The results look encouraging, but they’re not yet conclusive.
For people weighing options, the osteoarthritis treatment guide sets exosomes beside physical therapy, hyaluronic acid, PRP and joint replacement, and the joint pain condition page covers causes that need a diagnosis before any injection.
Skin Rejuvenation
Evidence Grade: Early
Exosomes are being marketed aggressively in aesthetic medicine. The proposed mechanism, stimulating collagen production, promoting angiogenesis, and enhancing skin cell turnover, makes biological sense. Small case series show improvements in skin texture and elasticity. But controlled trials comparing exosomes to established treatments like microneedling alone, PRP, or retinoids are largely absent. Marketing has far outpaced evidence here.
Hair Restoration
Evidence Grade: Early
The theory: exosome cargo activates dormant hair follicle stem cells, extends the anagen (growth) phase, and increases blood supply to the follicular unit. A handful of small studies show increased hair density and thickness, but head-to-head comparisons with PRP (which has more established evidence for androgenetic alopecia) are limited. If you’re considering exosomes for hair loss, understand that PRP currently has a stronger evidence base and lower cost. The closer look at exosome therapy for hair loss and the hair loss treatment guide cover the alternatives, including minoxidil and finasteride.
Neurological Conditions
Evidence Grade: Very Early
This is the area with the most exciting preclinical potential. Exosomes can cross the blood-brain barrier, something most therapeutics cannot do, making them a potential delivery vehicle for neuroprotective signals. Animal studies show improved neurological function and reduced neuroinflammation in traumatic brain injury (TBI) and stroke models. But human data is essentially nonexistent for neurological applications. This is years away from clinical validation.
⚠ Critical Safety Warning: FDA Alerts on Exosome Products: The FDA has issued multiple warnings about unapproved exosome products. In 2019, several patients were hospitalized after receiving contaminated exosome injections from an unregulated supplier. Key facts you need to know:
- No exosome products are FDA-approved for any clinical indication in the United States as of 2026.
- The FDA considers most exosome products to be biological products requiring an Investigational New Drug (IND) application.
- Quality, purity, and potency are not standardized across manufacturers. Some products marketed as “exosomes” contain minimal actual exosome content.
- Contamination risk is real: bacterial contamination, endotoxin contamination, and viral transmission have all been documented with poorly manufactured products.
- Any provider claiming their exosome products are “FDA-approved” is either misinformed or being dishonest. Walk away.
The FDA’s Public Safety Notification on Exosome Products of December 6, 2019 reported serious adverse events in patients in Nebraska treated with unapproved exosome products, identified with help from the CDC. The agency stated that exosomes used to treat diseases in humans are regulated as drugs and biological products under the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act. Patients and clinicians can report a reaction through the FDA’s MedWatch program.
Exosomes vs. PRP vs. Stem Cells: Comparison Table
Exosome therapy, PRP and stem cell therapy are often sold side by side, and they differ most in source, evidence and FDA status. PRP uses your own blood and has the most randomized trial data of the three; exosomes come from donor cells and have the least.
| Factor | Exosome Therapy | PRP Therapy | Stem Cell Therapy |
|---|---|---|---|
| What it is | Cell-free signaling vesicles from MSCs | Concentrated platelets from your own blood | Living cells (autologous or donor) |
| Mechanism | Paracrine signaling via microRNA + growth factors | Growth factor release from platelets | Cell engraftment + paracrine signaling |
| Source | Donor MSCs (usually umbilical cord) | Your own blood (autologous) | Your own tissue or donor |
| Evidence level | Early (preclinical + small studies) | Moderate to strong (multiple RCTs) | Moderate (growing RCT data) |
| FDA status | Not approved | Device-cleared (preparation systems) | Limited approvals (HCT/Ps) |
| Immune rejection risk | Very low | None (autologous) | Low to moderate (depends on source) |
| Typical cost | $3,000-$10,000+ | $500-$2,500 | $5,000-$25,000+ |
| Best current use | Investigational across multiple areas | Joint pain, hair loss, skin | Severe joint/tissue damage |
For a side-by-side on joints, skin and hair, the exosome therapy vs. PRP breakdown goes deeper, and the PRP treatment guide explains preparation systems and dosing.
What to Expect: Treatment Process and Recovery
If you decide to move forward with exosome therapy, here’s what a typical treatment experience looks like.
Before treatment: You’ll have a consultation reviewing your medical history, imaging (for orthopedic cases), and a candid discussion about what the evidence does and doesn’t support for your specific condition. Some providers recommend stopping NSAIDs one to two weeks before treatment, since anti-inflammatories may blunt the regenerative cascade.
The procedure itself: Joint injections take 15-30 minutes and feel similar to a cortisone injection: brief discomfort that most people tolerate well. Ultrasound guidance is standard for accuracy. IV infusions take 30-60 minutes. Skin treatments are typically combined with microneedling and take 30-60 minutes.
After treatment: Most people return to normal activities within 24-48 hours. For joint injections, avoid intense exercise for one to two weeks. Results aren’t immediate; expect four to eight weeks as the regenerative cascade unfolds. Multiple sessions are typically recommended (one to three treatments spaced four to six weeks apart).
Cost of Exosome Therapy
Exosome therapy is not covered by insurance. Pricing varies significantly based on the exosome source, quantity (measured in particle count), provider experience, and location.
| Application | Typical Cost Range | Sessions Usually Needed | Notes |
|---|---|---|---|
| Single joint injection | $3,000-$7,000 | 1-3 | Price per joint; bilateral treatment costs more |
| IV infusion (systemic) | $5,000-$15,000 | 1-3 | Higher particle counts increase cost |
| Facial/skin rejuvenation | $1,500-$5,000 | 2-4 | Often bundled with microneedling |
| Hair restoration | $2,000-$6,000 | 3-6 | Multiple sessions typically required for visible results |
Because exosome products are not FDA approved, health insurance, Medicare and Medicaid do not pay for them, and the consultation, imaging and ultrasound guidance may be billed separately. Ask for a written quote that names the product, the particle count per dose and the number of sessions before you agree to treatment.
Key Concept: Be Cautious of Unusually Low Pricing: Proper exosome preparation, characterization, and quality control are expensive processes. If a clinic is offering exosome therapy at a fraction of the market price, ask why. The product may contain minimal actual exosome content, lack proper quality testing, or come from an unverified source. The Certificate of Analysis is your best protection (more on that below).
How to Evaluate an Exosome Therapy Provider
Given the regulatory gray area, your due diligence matters enormously. Here’s what to ask and what to look for.
Request the Certificate of Analysis (CoA). This is non-negotiable. A legitimate exosome product should have documented particle counts (typically billions per dose), size distribution within the exosome range (30-150 nm), surface marker characterization (CD63, CD81, CD9 positive), sterility testing, and endotoxin testing. If a provider can’t produce this documentation, do not proceed.
Ask about the source. Where do the exosomes come from? Which tissue? Which lab processes them? Are they derived from MSCs or another cell type? How are they stored and handled?
Check credentials. The provider should be a licensed physician with specific training in regenerative medicine, not someone who attended a weekend seminar and added exosomes to their menu.
Evaluate their honesty. A good provider will acknowledge the limitations of the evidence and won’t promise results. If a product is described as “FDA-approved,” or an outcome is described as certain or permanent, treat it as a red flag and leave.
Check whether a trial fits. For serious or progressive disease, a registered study listed on ClinicalTrials.gov, the US registry run by the National Library of Medicine, offers oversight that a cash-pay clinic visit does not. Trials list their sponsor, phase and eligibility rules.
Regenerated.com is free for patients and lists clinics that record exosome therapy and related modalities. Listing order is not paid ranking, Featured slots are labeled and capped, and Verified means the clinic completed credential checks, not that it paid more. Inclusion is not an endorsement, so use the questions above with any clinic you find, and see how Featured, Verified and organic listings differ. Clinics offering related injections are listed in the PRP clinic directory.
Who Should Not Get Exosome Therapy
⚠ Safety Warning: Contraindications:
- Active cancer or recent cancer history: Exosomes carry growth-promoting signals. While MSC-derived exosomes have not been shown to cause cancer in available human studies, the theoretical risk of promoting existing tumor growth is significant enough that active malignancy is a clear contraindication.
- Active infections: Exosome-mediated immune modulation could interfere with the body’s infection response.
- Pregnancy or breastfeeding: No safety data exists in this population.
- Immunosuppressive therapy: Relative contraindication; requires careful evaluation and risk-benefit discussion with your provider.
People with a condition that has an established treatment they have not yet tried, such as physical therapy for early knee osteoarthritis or a disease-modifying drug for rheumatoid arthritis, are usually advised to start there. Bring the product name and Certificate of Analysis to your primary care physician or specialist before booking.
Frequently Asked Questions
What is exosome activation?
Exosome activation is the process in which an exosome binds to a target cell, is taken inside, and releases cargo that switches on repair signaling such as the AKT and ERK pathways. Zhang and colleagues showed this in a 2018 Biomaterials study, where MSC exosomes activated cartilage cells through the enzyme CD73. Clinics sometimes also use “activation” for mixing a freeze-dried exosome vial with sterile fluid, which is a preparation step and adds no tested benefit.
Are exosomes FDA approved?
No. As of 2026, no exosome therapy products are FDA-approved for any clinical use in the United States. Treatments are offered under the practice of medicine by licensed providers, but the products themselves lack regulatory approval, and the FDA regulates them as drugs and biological products that need premarket review. The agency’s December 2019 Public Safety Notification states that there are no FDA-approved exosome products. Any claim of FDA approval is false.
How long do exosome therapy results last?
Nobody knows yet, because long-term data does not exist for any application. For orthopedic applications, some patients report benefits lasting 6-12 months or longer. Skin and hair treatments typically require maintenance sessions every 6-12 months. Results vary considerably by application and individual, so treat any clinic estimate of duration as a rough expectation rather than a measured outcome from a controlled trial.
What are the side effects of exosome therapy?
The most common side effects are injection-site reactions, such as pain, swelling, and redness, which are typically mild and resolve within a few days. Infection risk exists with any injection procedure, and contaminated products have caused serious adverse events. The bigger concern is unknown long-term effects: exosome therapy is too new to know the consequences of repeated exposure over years.
Can exosome therapy cause cancer?
MSC-derived therapeutic exosomes have not been linked to cancer development in available human data, but that data is limited and short-term. Exosomes carry growth-promoting signals, and tumor-derived exosomes can promote cancer progression in preclinical models. If you have a personal or strong family history of cancer, discuss this thoroughly with your oncologist before proceeding, and treat active cancer as a reason not to proceed.
Are exosomes better than PRP?
Not necessarily. PRP has a significantly larger evidence base, particularly for knee osteoarthritis and androgenetic alopecia, where multiple randomized controlled trials exist. PRP is also autologous (from your own blood), eliminating concerns about product quality and contamination. Exosomes may theoretically offer advantages in signaling complexity, but until the human evidence catches up, PRP remains the better-supported option for most regenerative applications.
How do I know if the exosome product is legitimate?
Request the Certificate of Analysis (CoA). It should document particle count (typically billions per dose), size distribution (30-150 nm range), surface markers (CD63, CD81, CD9), sterility testing, and endotoxin testing. Ask which lab produced the exosomes and whether they follow GMP (Good Manufacturing Practice) standards. If the provider can’t or won’t provide this information, find a different provider.
How much does exosome therapy cost near me?
Prices range from $3,000 to $10,000 or more per session depending on the application, exosome source, particle count, and geographic location. Total treatment costs can range from $3,000 for a single joint injection to $30,000 or more for full multi-session IV protocols. This is entirely out of pocket, since no insurance covers exosome therapy, so ask each clinic for a written, itemized quote.
What is the difference between exosomes and stem cells?
Stem cells are living cells that can engraft, differentiate, and produce signals over extended periods. Exosomes are the signaling packages those cells release: they contain the messages but not the messenger. Exosomes cannot replicate, differentiate, or sustain long-term signaling the way living cells can. Think of it this way: stem cells are the factory, and exosomes are the products the factory ships out.
The Bottom Line
Exosome therapy sits at a genuinely interesting intersection of basic science and clinical potential. The biology is real: exosomes are fundamental to how cells communicate, and exosome activation of AKT and ERK signaling in target cells is well described in laboratory studies. But we are still in the early chapters of understanding how to use that biology therapeutically. The preclinical evidence is compelling. The clinical evidence is thin. And the gap between what some clinics claim and what the research actually supports is, frankly, troubling.
If you’re considering exosome therapy, go in with clear eyes: demand the Certificate of Analysis, verify your provider’s credentials and honesty, understand that you’re paying out of pocket for a treatment that remains investigational, and have realistic expectations. For many conditions, treatments like PRP or prolotherapy have stronger evidence at lower cost and should be considered first.
Related Topics
- Stem Cell Therapy: How it compares to exosome therapy and where the evidence is stronger
- PRP Therapy: The better-established regenerative option for joints and hair loss
- Prolotherapy: An affordable regenerative injection therapy with solid evidence for ligament and tendon injuries
- Joint Pain: A broader look at regenerative and integrative approaches to joint conditions
- Hair Loss: Evidence-based and integrative strategies for hair restoration
- Exosome Therapy Evidence: A study-by-study review of the published human research
Sources
- Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
- Zhu Y, et al. Exosome-based therapeutic strategies for musculoskeletal disorders. Bioactive Materials. 2023;22:532-546.
- FDA. Public Safety Notification on Exosome Products. 2019.
- Lener T, et al. Applying extracellular vesicles based therapeutics in clinical trials. J Extracell Vesicles. 2015;4:30087.
- Zhang S, et al. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials. 2018;156:16-27.
- Tao SC, et al. Exosomes derived from human platelet-rich plasma prevent apoptosis induced by glucocorticoid-associated endoplasmic reticulum stress in rat osteonecrosis of the femoral head via the Akt/Bad/Bcl-2 signal pathway. Theranostics. 2017;7(3):733-750.
- Vader P, et al. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev. 2016;106:148-156.
- Théry C, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018). J Extracell Vesicles. 2018;7(1):1535750.
- Zhuo H, et al. Advances in application of hypoxia-preconditioned mesenchymal stem cell-derived exosomes. Front Cell Dev Biol. 2024;12:1446050.
